Dr. Silverman serves as Vice President of Protein Sciences at Spotlight Therapeutics. He brings over 15 years of biotherapeutics preclinical research experience, with broad expertise in protein engineering, gene therapy, antibodies, and enzymes. Just prior to joining Spotlight, Dr. Silverman served as Senior Director, Therapeutics Discovery at Codexis, where he led the Biotherapeutics research team’s efforts to engineer enzyme replacement and gene therapies for treating inborn errors of metabolism and other metabolic disorders. Prior to Codexis, Dr. Silverman led the Protein and Antibody Engineering group at Denali Therapeutics where he played a key scientific and leadership role in building Denali’s blood-brain barrier ‘Transport Vehicle’ platform, which has been incorporated into multiple clinical-stage investigational therapies. Dr. Silverman started his biotech career at Takeda, where he held roles of increasing responsibility in therapeutic antibody discovery and engineering.

Dr. Silverman received a B.S. in Chemistry from Massachusetts Institute of Technology and a Ph.D. in Chemistry from Stanford University. He completed post-doctoral training in the Bioengineering department at Stanford.